Successful treatment of systemic and central nervous system lymphomatoid granulomatosis with rituximab. Leuk Lymphoma 2004 Apr;45(4):777-80
Date
05/27/2004Pubmed ID
15160955DOI
10.1080/10428190310001625854Scopus ID
2-s2.0-1342266161 (requires institutional sign-in at Scopus site) 54 CitationsAbstract
Lymphomatoid granulomatosis (LYG) is a rare lymphoproliferative disorder with a mortality rate approaching 60% in the first year. The median survival is 14 months from the time of diagnosis. Although a variety of chemotherapeutic regimens have been utilized, there is no standard treatment. Studies have shown that in most cases the malignant cells are B-cells, which induce massive infiltration of reactive T-lymphocytes in the background. The disease is therefore considered as a T-cell rich B-cell lymphoproliferative disorder. We report a case of LYG with pulmonary, hepatic, central and peripheral nervous system involvement that was successfully treated with the anti-CD20 (B-cell) monoclonal antibody, Rituximab.
Author List
Zaidi A, Kampalath B, Peltier WL, Vesole DHAuthor
Wendy L. Peltier MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antibodies, MonoclonalAntibodies, Monoclonal, Murine-Derived
B-Lymphocytes
Central Nervous System Neoplasms
Disease-Free Survival
Humans
Immunohistochemistry
Lymphomatoid Granulomatosis
Male
Middle Aged
Neoplasm Invasiveness
Remission Induction
Rituximab
T-Lymphocytes
Treatment Outcome
